Fangzhou
- Company typePublic
- Founded2015
- HeadquartersGuangzhou, China
- Headcount—
- GTM typeB2C
- OfferingDigital Commerce or Content
Fangzhou firmographics
Firmographics- Name
- Fangzhou
- Legal name
- Fangzhou Inc.
- Website
- https://jianke.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Ownership category
- akta.pro rank
Fangzhou industry classification
Industry- Product category
- Online Pharmacy and Digital Healthcare
- NAICS
- Pharmacies and Drug Retailers (456110), Pharmacies and Drug Retailers (45611)
- SIC
- Retail-Drug Stores And Proprietary Stores (5912), Services-Health Services (8000)
- akta.pro primary industry
- DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription) (HLALAIAA)
- akta.pro secondary industries
- Medication Adherence & Therapy Management Platforms (refills, reminders, MTM) (HLALAIAG), Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing (HLALAIAH)
Keywords
Where Fangzhou is headquartered
LocationHeadquarters
- HQ city
- Guangzhou
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
Fangzhou business model
Business model- GTM type
- B2C
- Offering type
- Digital Commerce or Content
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Online Pharmacy Retail: Direct-to-consumer online pharmacy sales through jianke.com platform. Customers purchase prescription and OTC medications, health products, medical devices, and supplements. Revenue generated from product sales with pricing varying by medication type and brand.
- Healthcare Services: Telemedicine consultation services connecting registered users with physicians. Platform facilitates online consultations, medication guidance, and health management services to registered users.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Individual product pricing varies by medication type and manufacturer |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Fangzhou product offering
Product offeringCore offering
Fangzhou operates a direct-to-consumer online pharmacy and digital healthcare platform selling prescription and OTC medications, health supplements, and medical devices through jianke.com. The platform provides telemedicine consultations with registered physicians and uses its proprietary XS LLM AI platform for chronic disease management. It serves over 59.8 million registered users and 282,000 physicians across China, primarily focused on chronic care patients requiring ongoing medication and monitoring.
Product overview
Fangzhou Inc. operates as a healthcare AI company with two main offerings: (1) AI-Powered Healthcare Solutions centered on the XS LLM Platform that automates patient and physician workflows for chronic disease management, and (2) 方舟健客 (Fangzhou Jianke) - a B2C online pharmacy ecosystem comprising the jianke.com e-commerce platform and the 健客医生 mobile app. The AI platform powers clinical decision support and healthcare automation, while the pharmacy platform provides online medication sales, health consultations, and patient monitoring services. The company serves over 59.8 million registered users with 282,000 registered physicians on its platform.
Differentiator
Problem solved
Functional benefit
Products and services
- Fangzhou Jianke Online Pharmacy (方舟健客网上药店) B2C online pharmacy platform where individual consumers nationwide can search, purchase, and receive prescription and OTC medications, health supplements, and medical devices, with pharmacist consultation support and prescription upload functionality.
- Jianke Doctor (健客医生)
Quantifiable outcome
- Revenue growth of 22.2% YoY reaching RMB 1.8245 billion in H1 2026
- +2 more outcomes
Companies that use Fangzhou
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Fangzhou technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature3 records
Fangzhou partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Tencent HealthcarecoreFangzhou and Tencent Healthcare launched an AI-powered chronic disease management solution combining Fangzhou's clinical expertise with Tencent's cloud infrastructure. The platform enables personalized patient monitoring and early complication detection, streamlining clinical workflows and reducing professional workload while improving patient outcomes within China's chronic care ecosystem.
- Novo NordiskcoreFangzhou and Novo Nordisk launched an initiative for AI-powered diabetes and weight management solutions at the 8th China International Import Expo (CIIE) in Shanghai. Fangzhou was recognized as an 'Outstanding Strategic Health Ecosystem Partner' for digital innovation in chronic disease management. The strategic partnership aims to integrate Fangzhou's AI infrastructure with Novo Nordisk's therapies to shift from disease-focused treatment to proactive health management.
- Multiple Pharmaceutical ManufacturerscoreFangzhou has established strategic partnerships with major pharmaceutical manufacturers to ensure direct supply of authentic products. These partnerships enable competitive pricing, product exclusivity, and reliable supply chain management. The company claims to have agreements with numerous large-scale drug manufacturers for direct procurement.
Scale indicators8 records
Recent moves6 records
Fangzhou competitors and assessment
Company assessmentDirect peers
- JD Health International: Hong Kong-listed Chinese online pharmacy and healthcare services platform with integrated telemedicine and chronic-disease management. Closest direct competitor to Fangzhou given overlapping DTC pharmacy model, AI-enabled healthcare ambitions and China-only footprint.
- Alibaba Health Information Technology: HKEX-listed arm of Alibaba operating China's largest healthcare e-commerce platforms alongside telehealth and chronic-care services. Competes head-on with Fangzhou's jianke.com on drug retail assortment, pricing and AI-driven consumer health experiences.
- Ping An Healthcare and Technology (Good Doctor): China-based online healthcare platform offering telemedicine consultations, chronic-care management and online pharmacy under the Ping An ecosystem. Highly relevant given comparable AI-enabled chronic-care strategy and integrated physician network.
- WeDoctor (We Doctor / Tencent Trusted Doctor): Major Chinese digital healthcare platform combining hospital appointment booking, telemedicine and chronic-disease management. Overlaps with Fangzhou in AI chronic care, physician network and DTC patient services within China.
- Dingdang Health (Dingdang Kuaiyao): China-focused online pharmacy with rapid-delivery prescription drug network and AI-powered chronic-care capabilities. Directly comparable to Fangzhou on DTC online pharmacy model and condition-specific digital health programs.
- 111 Inc. (1药网 / Yi Yao Wang): NASDAQ-listed Chinese digital healthcare platform offering online pharmacy, B2B drug distribution and chronic-disease management. Comparable to Fangzhou on integrated online pharmacy + chronic-care model targeting Chinese consumers.
Broad incumbents
- Hims & Hers Health: US-listed DTC telehealth and online pharmacy platform focused on condition-specific care (weight management, mental health, dermatology). Comparable business model — DTC pharmacy + AI-enabled chronic care subscriptions — though operating in the US rather than China.
Emerging players
- Lemonaid Health: US-based DTC telehealth platform offering online consultations, prescriptions and medication delivery for chronic and recurring conditions. Comparable to Fangzhou's physician-mediated DTC pharmacy + chronic-care model, though at smaller scale and different geography.
- Medlinker (医联): Chinese physician-community and chronic-disease management platform focused on connecting doctors with patients for condition-specific care programs. Comparable emerging player in the China AI-enabled chronic-care space, though smaller scale than Fangzhou.
Others
- Tencent Healthcare: Cloud infrastructure and AI solutions arm of Tencent serving Chinese healthcare providers and digital health platforms. Ecosystem partner to Fangzhou via the AI chronic-care solution, providing cloud and AI tooling comparable to what Fangzhou is building internally.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Fangzhou compliance and trust
Trust signalCompliance2 records
Fangzhou financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fangzhou leadership team
Management profileNumber of profiles
Fangzhou subsidiaries and ownership
Company hierarchySubsidiaries4 records
Fangzhou funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fangzhou M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fangzhou
What does Fangzhou do?
Fangzhou operates a direct-to-consumer online pharmacy and digital healthcare platform selling prescription and OTC medications, health supplements, and medical devices through jianke.com. The platform provides telemedicine consultations with registered physicians and uses its proprietary XS LLM AI platform for chronic disease management. It serves over 59.8 million registered users and 282,000 physicians across China, primarily focused on chronic care patients requiring ongoing medication and monitoring.
Is Fangzhou a public or private company?
Fangzhou is a public company. It is classified as public and is currently operating.
When was Fangzhou founded?
Fangzhou was founded in 2015.
Where is Fangzhou based?
Fangzhou is headquartered in Guangzhou, China, in the Asia region.
How does Fangzhou make money?
Two revenue lines are on record. Online Pharmacy Retail is the primary driver. The others are healthcare Services.
Who are Fangzhou's main competitors?
Direct peers on record are JD Health International, Alibaba Health Information Technology, Ping An Healthcare and Technology (Good Doctor), WeDoctor (We Doctor / Tencent Trusted Doctor), Dingdang Health (Dingdang Kuaiyao) and 111 Inc. (1药网 / Yi Yao Wang). Hims & Hers Health is listed as a broad incumbent. Emerging players are Lemonaid Health and Medlinker (医联). Tencent Healthcare is listed as an others.
Does Fangzhou have an API?
No public API is recorded for Fangzhou.
What industry is Fangzhou in?
Fangzhou's product category is Online Pharmacy and Digital Healthcare. Its primary akta.pro industry code is HLALAIAA, DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription), with a secondary code of HLALAIAG, Medication Adherence & Therapy Management Platforms (refills, reminders, MTM). Its NAICS code is 456110 and its SIC code is 5912.